Melissa G Collier1, Jan Drobeniuc2, Jazmine Cuevas-Mota3, Richard S Garfein3, Saleem Kamili2, Eyasu H Teshale2. 1. Centers for Disease Control and Prevention, National Center for HIV, Hepatitis, STD, and TB Prevention, Division of Viral Hepatitis, Atlanta, GA, United States. Electronic address: mgcollier@cdc.gov. 2. Centers for Disease Control and Prevention, National Center for HIV, Hepatitis, STD, and TB Prevention, Division of Viral Hepatitis, Atlanta, GA, United States. 3. Division of Global Public Health, School of Medicine, University of California, San Diego, CA, United States.
Abstract
BACKGROUND: Our study aims were to assess hepatitis A virus (HAV) and hepatitis B virus (HBV) susceptibility and infection among young persons who inject drugs (PWID) who may have been vaccinated as children and to evaluate self-report of HAV and HBV vaccination. METHODS: We recruited PWID aged 18-40 years-old in San Diego during 2009 and 2010 and collected demographic, socioeconomic, health, and behavioral factors. Participants were asked if they had been vaccinated against HAV and HBV, and serum samples were collected for HAV and HBV serologic testing. RESULTS: Of 519 participants, 365 (72%) were male, 252 (49%) were white non-Hispanic, 38 (7%) were Black non-Hispanic, 138 (27%) were White Hispanic, and 22 (4%) were born outside the U. S. Of the total participants, 245 (47%) had surface hepatitis B antibody (anti-HBs) titers <10mIU/ml (i.e., HBV susceptible) and 325 (63%) had no detectable HAV antibodies (HAV susceptible). Hepatitis B surface antigen was detected in 7 (1%) of total participants; and 135 (26%) were anti-HCV-antibody positive. Compared to serologic findings, self-report of HBV and HAV vaccination was 71% and 41% sensitive, and 58% and 73% specific, respectively. CONCLUSION: HAV and HBV antibodies in half or more of this young PWID population did not have levels indicative of protection, and about a quarter had HCV infection, putting them at risk for complications resulting from co-infection with HAV or HBV. Programs serving this population should vaccinate PWIDs against HAV and HBV and not rely on self-report of vaccination. Published by Elsevier Ltd.
BACKGROUND: Our study aims were to assess hepatitis A virus (HAV) and hepatitis B virus (HBV) susceptibility and infection among young persons who inject drugs (PWID) who may have been vaccinated as children and to evaluate self-report of HAV and HBV vaccination. METHODS: We recruited PWID aged 18-40 years-old in San Diego during 2009 and 2010 and collected demographic, socioeconomic, health, and behavioral factors. Participants were asked if they had been vaccinated against HAV and HBV, and serum samples were collected for HAV and HBV serologic testing. RESULTS: Of 519 participants, 365 (72%) were male, 252 (49%) were white non-Hispanic, 38 (7%) were Black non-Hispanic, 138 (27%) were White Hispanic, and 22 (4%) were born outside the U. S. Of the total participants, 245 (47%) had surface hepatitis B antibody (anti-HBs) titers <10mIU/ml (i.e., HBV susceptible) and 325 (63%) had no detectable HAV antibodies (HAV susceptible). Hepatitis B surface antigen was detected in 7 (1%) of total participants; and 135 (26%) were anti-HCV-antibody positive. Compared to serologic findings, self-report of HBV and HAV vaccination was 71% and 41% sensitive, and 58% and 73% specific, respectively. CONCLUSION:HAV and HBV antibodies in half or more of this young PWID population did not have levels indicative of protection, and about a quarter had HCV infection, putting them at risk for complications resulting from co-infection with HAV or HBV. Programs serving this population should vaccinate PWIDs against HAV and HBV and not rely on self-report of vaccination. Published by Elsevier Ltd.
Entities:
Keywords:
Hepatitis C virus; Persons who inject drugs; Self-report
Authors: Ruth Koepke; Danielle N Sill; Wajiha Z Akhtar; Kailynn P Mitchell; Sheila M Guilfoyle; Ryan P Westergaard; Stephanie L Schauer; James M Vergeront Journal: Public Health Rep Date: 2019-09-20 Impact factor: 2.792
Authors: Emmanuelle A Dankwa; Christl A Donnelly; Andrew F Brouwer; Rui Zhao; Martha P Montgomery; Mark K Weng; Natasha K Martin Journal: Vaccine Date: 2021-10-20 Impact factor: 4.169
Authors: Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris Journal: MMWR Recomm Rep Date: 2020-07-03
Authors: Delia Motavalli; Jessica L Taylor; Ellen Childs; Pablo K Valente; Peter Salhaney; Jennifer Olson; Dea L Biancarelli; Alberto Edeza; Joel J Earlywine; Brandon D L Marshall; Mari-Lynn Drainoni; Matthew J Mimiaga; Katie B Biello; Angela R Bazzi Journal: J Gen Intern Med Date: 2020-09-11 Impact factor: 5.128
Authors: Jessica L Taylor; Samantha Johnson; Ricardo Cruz; Jessica R Gray; Davida Schiff; Sarah M Bagley Journal: J Gen Intern Med Date: 2021-06-22 Impact factor: 5.128